Cytori Therapeutics Inc (NASDAQ:CYTX) announced Dr. Ramón Cugat MD, Ph.D. will present 12-month follow-up results from a 20-patient, single arm, open label pilot study on the use of Cytori Cell Therapy in anterior cruciate ligament (ACL) reconstruction. The presentation is titled ‘Biological Augmentation of ACL Reconstruction’ and will be made to The Orthobiologic Institute (TOBI) 7th Annual PRP and Regenerative Medicine Symposium in Las Vegas onJune 10, 2016.

Patients in the study had sports-related injuries leading to complete rupture of their ACL, a relatively common sports injury that can impact the long-term careers of professional athletes as well as the ability of non-professional athletes to participate in active lifestyles. All patients in the study received Cytori Cell Therapy as an adjunct to bone-patellar tendon-bone grafting to reconstruct the ACL. Data to be presented include safety, feasibility, patient-reported outcomes related to activity levels and pain as well as serial magnetic resonance imaging (MRI) of the knee through one year. Data have been compared to a historical control group of similar patients treated at the same center by the same surgical team using the same procedure without supplementation with Cytori Cell Therapy.

Dr. Ramón Cugat is internationally-recognized for his expertise in orthopedics, sports medicine and the treatment of orthopedic trauma in elite soccer players. He is currently President of the Medical Councilat the Catalan Mutual Insurance of Football under the Royal Spanish Football Federation and a recent inductee as a full academician into the Royal European Academy of Doctors. In addition, he is currentlyCo-Director of the Department of Orthopaedic Surgery and Traumatology at the Hospital Quiron in Barcelona, Spain and on the faculty of the Department of Surgery and Regenerative Medicine at the Universidad CEU Cardenal Herrera in Valencia, Spain. He has published more than 100 papers and multiple book chapters. (Original Source)

Shares of Cytori closed yesterday at $2.32, down $0.07 or -2.93%. CYTX has a 1-year high of $10.50 and a 1-year low of $1.92. The stock’s 50-day moving average is $3.54 and its 200-day moving average is $3.30.

On the ratings front, CYTX has been the subject of a number of recent research reports. In a report issued on March 28, Maxim Group analyst Jason Kolbert reiterated a Buy rating on CYTX, with a price target of $75, which implies an upside of 3132.8% from current levels. Separately, on March 24, Roth Capital’s Joseph Pantginis maintained a Buy rating on the stock and has a price target of $22.50.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Joseph Pantginis have a total average return of -14.9% and 9.8% respectively. Kolbert has a success rate of 30.4% and is ranked #3902 out of 3903 analysts, while Pantginis has a success rate of 39.2% and is ranked #170.

Cytori Therapeutics, Inc. is a late stage cell therapy company. Its develops autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair.